Ascendis Pharma A/S
ASND
Clasificación en acciones
#1496
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Precio por acción
$234.15
Última sincronización: 2026-10-20
Capitalización bursátil
$14.61B
Cambio (1 día)
1.82%
Cambio (1 año)
16.73%
País
DK
Comercio Ascendis Pharma A/S (ASND)
Categoría
Healthcare
Ingresos de Ascendis Pharma A/S (ASND)
Ingresos en Jun 2026 TTM: $1.25B
Según los últimos informes financieros de Ascendis Pharma A/S, los ingresos actuales de la empresa (TTM) son $1.25B. En 2024, la empresa obtuvo unos ingresos de $378.39M un aumento con respecto a los ingresos del año 2023, que fueron de $294.85M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Ascendis Pharma A/S desde 2012 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.25B | 54.10% |
| 2025 | $811.56M | 114.48% |
| 2024 | $378.39M | 28.34% |
| 2023 | $294.85M | 437.13% |
| 2022 | $54.89M | 520.63% |
| 2021 | $8.84M | 4.45% |
| 2020 | $8.47M | -43.57% |
| 2019 | $15.01M | 23.42% |
| 2018 | $12.16M | 562.32% |
| 2017 | $1.84M | -62.12% |
| 2016 | $4.85M | -45.02% |
| 2015 | $8.81M | -47.90% |
| 2014 | $16.92M | -39.71% |
| 2013 | $28.06M | 36.53% |
| 2012 | $20.56M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 909.42% |
US
|
|
| $2.23B | 78.15% |
US
|
|
| $15.74B | 1,158.89% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 381.45% |
NL
|
